Where Science Meets Compliance
Molecularity helps biotechnology, pharmaceutical, medical device, and healthcare organizations navigate quality, regulatory, and clinical compliance challenges — grounded in science, not just standards.
Molecular biology foundation
behind every recommendation
GxP systems built for
sustainable compliance
Strategic guidance across
FDA, EMA, and MHRA
Molecularity was founded to bridge a persistent gap in the life sciences consulting industry: advisors who understand either the regulatory framework or the underlying biology, but rarely both with equal depth.
Founded by a molecular biologist and regulatory affairs professional with 15+ years of industry experience, Molecularity provides strategic support across the full product lifecycle — from early development through commercial operations and post-approval.
Whether you are preparing for an FDA inspection, building a quality management system, qualifying a critical CDMO, or navigating a complex biologics submission, Molecularity delivers practical, science-driven solutions tailored to your organization's stage of growth and risk profile.
Molecularity operates as an independent consultancy, providing the objectivity and senior-level attention that large firms cannot offer.
PhD, Cellular & Molecular Biology
Regulatory Affairs Certified (RAC-US)
15+ Years in Quality & Regulatory Leadership
Published Scientific Author
FDA, EMA, and MHRA Inspection Support
NDA, BLA, IND, and 510(k) Submission Experience
Biologics, Cell & Gene Therapy Expertise
Clinical Research & GCP Audit Leadership
Molecularity provides practical, risk-based compliance solutions tailored to your product type, development stage, and regulatory environment.
FDA regulatory strategy, IND, NDA, BLA, and 510(k) support, orphan drug programs, submission review, and regulatory gap assessments.
QMS development, SOP authoring, CAPA systems, internal audit programs, quality metrics, and risk management frameworks.
FDA inspection readiness, mock inspections, PAI and PLI support, FDA response strategy, and remediation program management.
GCP, GMP, GLP, GCLP, pharmacovigilance, CSV, TMF, investigator site, CRO, and CMO/CDMO audits.
Vendor qualification, supplier audits, quality agreements, risk assessments, and ongoing oversight programs.
Specialized support for biologics, cell therapies, gene therapies, rare disease programs, and CMC quality in complex modalities.
Clinical quality systems, GCP compliance, TMF assessments, vendor oversight, and clinical inspection readiness.
Data integrity assessments, 21 CFR Part 11 compliance, CSV/CSA, eQMS and eDMS implementation support.
Privacy program development, risk assessments, policy development, workforce training, and incident response support.
Molecularity brings relevant, sector-specific experience across the organizations that develop and deliver innovative therapies.
Molecularity actively advances industry thinking in quality systems, regulatory science, and inspection readiness.
Developing fit-for-purpose quality frameworks for RWE studies, where traditional GCP structures require adaptation.
Practical approaches to building sustained inspection readiness rather than point-in-time preparation programs.
Applying ICH Q9 and Q10 principles pragmatically across organizations at varying stages of quality maturity.
Governance frameworks for complex outsourced operations, including CDMO qualification and ongoing performance oversight.
Navigating the evolving regulatory landscape for cell and gene therapies, biologics, and rare disease programs.
Implementing sustainable data governance and integrity programs that satisfy FDA and EMA expectations.
Whether you are preparing for an FDA inspection, building a quality system, qualifying a critical vendor, responding to findings, or navigating a complex regulatory pathway — Molecularity can help.
Schedule a consultation to discuss your organization's specific needs and how Molecularity can support your compliance goals.
Edgewater, Maryland | Remote & On-Site Available
www.molecularity.org
#contact